• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

UnitedHealth Group Launches New Digital Health Therapy for Type 2 Diabetes

by Fred Pennic 07/13/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
UnitedHealth Group Launches New Digital Health Therapy for Type 2 Diabetes

What You Should Know:

– UnitedHealth Group launches a new pilot for digital health therapy for Type 2 Diabetes to nearly a quarter-million members at no additional cost to more than 230,000 employer-sponsored, fully insured UnitedHealthcare members in 27 states and Washington, D.C.

– The therapy, known as Level2, helps participants gain real-time insights about their condition and, for some, successfully reduces spikes in blood sugar levels or achieves Type 2 Diabetes remission.

– The pilot offers a combination of real-time glucose monitoring, lifestyle changes, and one-on-one coaching to help people stabilize blood sugar levels and flag potential COVID-19 infections


UnitedHealth Group, today announced the launch of an innovative new therapy that combines wearable technology and customized personal support to help improve the health of people living with type 2 diabetes. The therapy — known as Level2 — helps eligible participants gain real-time insights about their condition and, for some, successfully reduce spikes in blood sugar levels or even achieve type 2 diabetes remission.

Level 2 Overview

Level2 equips eligible participants with integrated tools that include a mobile continuous glucose monitor (CGM), activity tracker, app-based alerts, and one-on-one clinical coaching to help encourage healthier lifestyle decisions, such as food choices, exercise and sleep patterns. In the future, the UnitedHealth Group may offer the Level2 model to support people with other chronic conditions beyond type 2 diabetes.

Through Level2, the combination of wearable technology, clinical coaching, lifestyle changes, and incentives — all offered at no additional cost to eligible UnitedHealthcare members who enroll — is designed to help empower people with type 2 diabetes to become healthier and potentially achieve remission. This is accomplished by helping participants use the latest scientifically proven techniques and personalized support to understand and more effectively stabilize blood sugar levels.

Importance of Maintaining Appropriate Blood Sugar Levels

Maintaining appropriate blood sugar levels, as measured by hemoglobin A1C, is a key focus for people with diabetes. This is especially critical now, as Type 2 diabetes is a significant risk factor for those infected with COVID-19, and the therapy has demonstrated an ability to improve the health of those living with the disorder.

Initial Pilot Results

In a pilot study of more than 790 UnitedHealthcare members, certain Level2 participants achieved a clinically meaningful reduction in their A1C within 90 days. Participants who began this therapy with the most significantly elevated A1C (above 8.0%) saw the greatest reduction (more than 1 percentage point decrease on average). By helping participants better control blood sugar levels and, in certain cases, achieve type 2 diabetes remission, some Level2 participants no longer require medication for their condition. To date, Level2 has helped participants improve their health to the degree they eliminated the need for more than 450 prescriptions.

Initial studies show that sudden changes in blood sugar levels among people with type 2 diabetes may indicate potential COVID-19 infections. Closely monitoring this metric among Level2 participants and supporting people at greater risk for COVID-19 complications, Level2 has demonstrated the ability to predict potential COVID-19 infections and help encourage access to needed medical care earlier. Type 2 diabetes may be a risk factor associated with worse outcomes related to COVID-19. However, people with type 2 diabetes whose blood sugar is stable may experience fewer medical complications and greater likelihood of recovery from COVID-19.

Participant Story

Jon Alger, 63, a Florida-based participant and software consultant who tested positive for the coronavirus in March, said Level2 was instrumental in helping him recover from COVID-19. “By helping me to better understand and monitor my glucose levels, Level2 encouraged me to eat at the appropriate times and helped me make better choices.”

Availability/Cost

More than 230,000 UnitedHealthcare employer-sponsored, fully insured health plan participants in 27 states and Washington D.C. are now eligible for Level2 at no additional cost. Participants enrolled in some employer-sponsored health plans may earn financial incentives, including cash or gift cards, by taking actions such as consistently wearing a CGM; completing post-meal walks; interacting with an assigned coach, and following personalized recommendations. Available incentives may vary by state and health plan type/design; eligible incentives offered through Level2 may be in addition to other well-being rewards available through the participants’ health benefits.

Future Expansion Plans

This multifaceted therapy is being expanded on a pilot basis to select plan participants enrolled in eligible employer-sponsored, fully insured health plans in the following markets: Arizona, Arkansas, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Missouri, Nebraska, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, Washington, D.C., West Virginia, and Wisconsin. Level2 will be made available to select employers with self-funded plans later this year.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |